976 related articles for article (PubMed ID: 19167259)
41. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
42. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
43. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
44. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
[TBL] [Abstract][Full Text] [Related]
45. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
46. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
47. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
48. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
49. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
[TBL] [Abstract][Full Text] [Related]
50. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
51. Pharmacotherapy for Parkinson's disease.
Chen JJ; Swope DM
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
[TBL] [Abstract][Full Text] [Related]
52. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
53. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
54. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
55. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
57. Determination of minimal clinically important change in early and advanced Parkinson's disease.
Hauser RA; Auinger P;
Mov Disord; 2011 Apr; 26(5):813-8. PubMed ID: 21437987
[TBL] [Abstract][Full Text] [Related]
58. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
59. Mid-stage parkinsonism with mild motor fluctuations.
Tolosa E; Valldeoriola F
Clin Neuropharmacol; 1994; 17 Suppl 2():S19-31. PubMed ID: 9358192
[TBL] [Abstract][Full Text] [Related]
60. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]